Difference between revisions of "CD20"
Jump to navigation
Jump to search
(create) |
|||
| Line 4: | Line 4: | ||
===Negative B cell lymphoma=== | ===Negative B cell lymphoma=== | ||
*[[Plasmablastic lymphoma]].<ref name=pmid15520070>{{Cite journal | last1 = Teruya-Feldstein | first1 = J. | last2 = Chiao | first2 = E. | last3 = Filippa | first3 = DA. | last4 = Lin | first4 = O. | last5 = Comenzo | first5 = R. | last6 = Coleman | first6 = M. | last7 = Portlock | first7 = C. | last8 = Noy | first8 = A. | title = CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients. | journal = Ann Oncol | volume = 15 | issue = 11 | pages = 1673-9 | month = Nov | year = 2004 | doi = 10.1093/annonc/mdh399 | PMID = 15520070 }}</ref> | *[[Plasmablastic lymphoma]].<ref name=pmid15520070>{{Cite journal | last1 = Teruya-Feldstein | first1 = J. | last2 = Chiao | first2 = E. | last3 = Filippa | first3 = DA. | last4 = Lin | first4 = O. | last5 = Comenzo | first5 = R. | last6 = Coleman | first6 = M. | last7 = Portlock | first7 = C. | last8 = Noy | first8 = A. | title = CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients. | journal = Ann Oncol | volume = 15 | issue = 11 | pages = 1673-9 | month = Nov | year = 2004 | doi = 10.1093/annonc/mdh399 | PMID = 15520070 }}</ref> | ||
*ALK+ large B-cell lymphoma. | |||
*Classical [[Hodgkin's lymphoma]]. | *Classical [[Hodgkin's lymphoma]]. | ||
Revision as of 15:34, 5 March 2017
CD20 is a B-cell marker. It is positive in most B-cell lymphoma.
Lymphomas
Negative B cell lymphoma
- Plasmablastic lymphoma.[1]
- ALK+ large B-cell lymphoma.
- Classical Hodgkin's lymphoma.
See also
References
- ↑ Teruya-Feldstein, J.; Chiao, E.; Filippa, DA.; Lin, O.; Comenzo, R.; Coleman, M.; Portlock, C.; Noy, A. (Nov 2004). "CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients.". Ann Oncol 15 (11): 1673-9. doi:10.1093/annonc/mdh399. PMID 15520070.